Ticagrelor in ST-Elevation Myocardial Infarction

Author(s): Gregory A. Sgueglia, Giuseppe Tarantini, Giampaolo Niccoli

Journal Name: Current Vascular Pharmacology

Volume 10 , Issue 4 , 2012

Become EABM
Become Reviewer
Call for Editor


Ticagrelor is a new oral antagonist of the platelet P2Y12 receptor that offers several potential advantages compared to clopidogrel including faster and more effective inhibition of platelet aggregation. Ticagrelor has been compared to clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial in a broad population of patients with acute coronary syndrome showing a reduction of the 12-month risk of death from vascular causes, myocardial infarction and stroke without increasing the overall risk of major bleeding. In a subanalysis of the PLATO trial focusing on patients with ST-elevation myocardial infarction, ticagrelor results were consistent with those of the overall trial. Additionally, possible pleiotropic effects of ticagrelor, including an appealing interaction with adenosine, might constitute a specific advantage in this particular subset of patients

Keywords: Ticagrelor, ST-elevation myocardial infarction, PLATO, P2Y12 receptor, clopidogrel, platelet aggregation, acute coronary syndrome, thrombolysis, percutaneous coronary intervention, thienopyridine

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 23 May, 2012
Page: [458 - 462]
Pages: 5
DOI: 10.2174/157016112800812728
Price: $65

Article Metrics

PDF: 10